Status:
COMPLETED
Clinical Study on Huatuo Zaizao Pills for Post-stroke Treatment
Lead Sponsor:
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Conditions:
Ischemic Stroke
Eligibility:
All Genders
35-75 years
Phase:
PHASE4
Brief Summary
The purpose of this study was to evaluate the improvement of limb motor function and nerve function of patients with HTZZ during stroke rehabilitation. A total of 80 subjects will be randomly assigned...
Detailed Description
This is a prospective, randomized controlled clinical trial. Eighty patients with phlegm and blood stasis block syndrome of ischemic stroke were randomly assigned to Hua Hua reconstruction group or co...
Eligibility Criteria
Inclusion
- Aged between 35 and 75 years old
- With a disease course between 2 weeks- 24weeks
- Meeting the diagnostic criteria of ischemic stroke
- Signed and dated written informed consent.
- 4≤NIHSS score≤22
Exclusion
- Unstable vital signs, or serious heart, liver, lung, kidney and other organ diseases
- Exclude Transient Ischemic Attack(TIA)
- Patients who are participating in clinical trials of other drugs within the past 1 month
- Pregnant or breastfeeding women
- Athletes, Epileptics, Allergic to this product
Key Trial Info
Start Date :
May 31 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 30 2023
Estimated Enrollment :
80 Patients enrolled
Trial Details
Trial ID
NCT04910256
Start Date
May 31 2021
End Date
September 30 2023
Last Update
November 29 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Xiyuan Hospital, China Academy of Chinese Medical Sciences
Beijing, Beijing Municipality, China, 10091